Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide 40

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    267 result(s) found for: Cyclophosphamide 40. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003931-40 Sponsor Protocol Number: BRD/05/95 Start Date*: 2006-04-20
    Sponsor Name:University College London
    Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma
    Medical condition: Angioimmunoblastic T-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001965-41 Sponsor Protocol Number: BRD/06/052 Start Date*: 2008-09-05
    Sponsor Name:University College London
    Full Title: Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004897-77 Sponsor Protocol Number: 0068-20 Start Date*: 2021-09-13
    Sponsor Name:Intas Pharmaceuticals Ltd.
    Full Title: A multicentric, open label, balanced, randomized, two-stage, two-treatment, two-period, two-sequence, crossover, multiple oral dose, comparative bioavailability study of cyclophosphamide powder for...
    Medical condition: Adult female patients with breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2004-001263-22 Sponsor Protocol Number: YMB1002-02 Start Date*: 2005-01-07
    Sponsor Name:YM Biosciences Inc
    Full Title: A Phase III study of DPPE (Temilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First – line Treatment in Metastatic/Recurrent Cancer
    Medical condition: Metastatic and/or recurrent cancer of the breast
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003610-15 Sponsor Protocol Number: RITUXVAS Start Date*: 2005-12-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, randomised, open trial comparing a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.
    Medical condition: Anti neutophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000709-12 Sponsor Protocol Number: C19562/2037/BC/EU Start Date*: 2008-05-27
    Sponsor Name:Cephalon France
    Full Title: Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and...
    Medical condition: Patients with human epidermal growth factor receptor-2 (HER2) positive stage II or III breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) AT (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002684-25 Sponsor Protocol Number: SICOG13/01 Start Date*: 2014-03-19
    Sponsor Name:S.I.C.O.G. ONLUS
    Full Title: Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced ...
    Medical condition: Local advanced breast cancer resectable, neoadjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001250-40 Sponsor Protocol Number: ICORG07-01 Start Date*: 2008-08-18
    Sponsor Name:Cancer Trials Ireland
    Full Title: An open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide, And Rituximab in Patients with Chronic Lymphocytic Leukaemia who are Newly Diagnosed, ha...
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005213-39 Sponsor Protocol Number: CJP4.2 Start Date*: 2013-04-10
    Sponsor Name:CENTRE JEAN PERRIN
    Full Title: Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and T...
    Medical condition: Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002377-21 Sponsor Protocol Number: M14-011 Start Date*: 2014-11-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) HU (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003588-69 Sponsor Protocol Number: W2018.034 Start Date*: 2019-03-07
    Sponsor Name:Leiden University Medical Center
    Full Title: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis
    Medical condition: ANCA associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001569-33 Sponsor Protocol Number: LLC-R-FCM-1 Start Date*: 2005-09-23
    Sponsor Name:Dept. Hematology, Hospital Clinic
    Full Title: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamie...
    Medical condition: Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003174-27 Sponsor Protocol Number: RC13-0284 Start Date*: 2014-06-12
    Sponsor Name:CHU de Nantes
    Full Title: A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TR...
    Medical condition: Young untreated patients with Multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-005177-21 Sponsor Protocol Number: 2015-29 Start Date*: 2016-01-28
    Sponsor Name:Assistance Publique Hôpitaux de MARSEILLE
    Full Title: Dose-Finding of Propranolol in combination with metronomic fixed oral cyclophosphamide based on Bivariate efficacy-tolerability outcome in patients with locally advanced or metastatic angiosarcoma ...
    Medical condition: Patients presenting angiosarcomas disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003539-68 Sponsor Protocol Number: 2011/090/HP Start Date*: 2012-02-09
    Sponsor Name:CHU-HOPITAUX DE ROUEN
    Full Title: ETUDE PROSPECTIVE RANDOMISEE COMPARATIVE PREDNISONE/ CYCLOPHOSPHAMIDE VERSUS PREDNISONE/ RITUXIMAB AU COURS DE L'HEMOPHILIE ACQUISE
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10053745 Acquired haemophilia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003435-13 Sponsor Protocol Number: MARLENE Start Date*: 2021-05-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer
    Medical condition: HER2 negative hormone receptors positive metastatic breast cancer progressed after CDK 4/6 inhibitors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007310 Carcinoma breast stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004969-27 Sponsor Protocol Number: 69HCL17_0028 Start Date*: 2018-05-28
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Infli...
    Medical condition: anterior idiopathic scleritis or anterior and posterior idiopathic scleritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10039705 Scleritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005375-15 Sponsor Protocol Number: MCL elderly Start Date*: 2006-04-21
    Sponsor Name:GELA
    Full Title: Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation
    Medical condition: Mantle cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000515-24 Sponsor Protocol Number: RG_17-247 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
    Medical condition: Rhabdomyosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000173-77 Sponsor Protocol Number: 2013-000173-77 Start Date*: 2014-02-12
    Sponsor Name:Institut Jules Bordet
    Full Title: TRIUMPH Trial A phase II TRial evalUating the Menstrual and ovarian function of young breast cancer patients treated with a cycloPHosphamide-free regimen composed of doxorubicin and paclitaxel
    Medical condition: Primary breast cancer (adjuvant or neoadjuvant)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 09:29:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA